A novel aptamer developed for breast cancer cell internalization

ChemMedChem. 2012 Jan 2;7(1):79-84. doi: 10.1002/cmdc.201100457. Epub 2011 Dec 14.

Abstract

Breast cancer affects one in eight women in the United States, with a mortality rate that is second only to lung cancer. Although chemotherapy is widely used in breast cancer treatment, its side effects remain a challenge. One way to address this problem is through drug delivery by the internalization of cell-type-specific probes. Although nucleic acid aptamers are excellent probes for molecular recognition, only a few studies have demonstrated that aptamers can be internalized into living cells. Therefore, herein we report the development of a cancer-cell-specific DNA aptamer probe, KMF2-1a. By using the cell-SELEX method, this aptamer was selected against breast cancer cell line MCF-10AT1. Our results show that KMF2-1a is internalized efficiently and specifically to the endosome of target breast cancer cells. These results indicate that KMF2-1a is a promising agent for cell-type-specific intracellular delivery with both diagnostic and therapeutic implications.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aptamers, Nucleotide / chemistry
  • Aptamers, Nucleotide / metabolism*
  • Breast Neoplasms / drug therapy*
  • Cell Line, Tumor
  • Drug Delivery Systems*
  • Endosomes / metabolism
  • Female
  • Humans
  • SELEX Aptamer Technique

Substances

  • Aptamers, Nucleotide